Professor Peter Horby and Professor Martin Landray, chief investigators of the RECOVERY trial, said: "In March this year, RECOVERY was established as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. "The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. Last night, the Committee recommended the chief investigators review the unblinded data on the hydroxychloroquine arm of the trial. "We have therefore decided to stop enrolling participants to the hydroxychloroquine arm of the RECOVERY trial with immediate effect." (Image: AFP via Getty Images)"Today’s preliminary results from the RECOVERY trial are quite clear – hydroxychloroquine does not reduce the risk of death among hospitalised patients with this new disease.

Source: Daily Mirror June 05, 2020 13:59 UTC